Radiotherapy Plus Chemotherapy Is Associated With Improved Survival Compared to Radiotherapy Alone in Patients With Primary Vaginal Carcinoma: A Retrospective SEER Study
| Autor: | Yang-yang Yue, Wei-li Zhou |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
squamous cell carcinoma
medicine.medical_specialty Cancer Research medicine.medical_treatment overall survival Urology Subgroup analysis chemotherapy lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine cancer-specific survival medicine Stage (cooking) Survival analysis radiotherapy Original Research Chemotherapy 030219 obstetrics & reproductive medicine adenocarcinoma business.industry Proportional hazards model lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease primary vaginal carcinoma Radiation therapy SEER Oncology 030220 oncology & carcinogenesis Cohort Adenocarcinoma business |
| Zdroj: | Frontiers in Oncology Frontiers in Oncology, Vol 10 (2020) |
| ISSN: | 2234-943X |
| DOI: | 10.3389/fonc.2020.570933 |
| Popis: | BackgroundThe efficacy of radiotherapy plus chemotherapy (RTCT) versus radiotherapy alone (RT) in the treatment of primary vaginal carcinoma has been controversial. We aimed to evaluate the up-to-date efficacy of RTCT on primary vaginal carcinoma in a real-world cohort.MethodsWe performed a retrospective analysis in patients with primary vaginal carcinoma retrieved from the Surveillance, Epidemiology, and End Results Program database from 2004 to 2016. Kaplan–Meier survival curves were plotted and compared by the log-rank test. Inverse probability weighting (IPW)-adjusted multivariate Cox proportional hazards and Fine-Gray competing-risk model was applied.ResultsOf the 1,813 qualified patients with primary vaginal carcinoma from 2004 to 2016, 1,137 underwent RTCT and 676 underwent RT. The median survival time was 34 months for the RT group and 63 months for the RTCT group. RTCT was significantly associated with improved overall survival (unadjusted HR = 0.71, 95% CI 0.62–0.82, p < 0.001; adjusted HR = 0.73, 95% CI 0.63–0.84, p < 0.001) and cancer-specific survival (unadjusted sHR = 0.81, 95% CI 0.69–0.95, p = 0.012; adjusted sHR = 0.81, 95% CI 0.69–0.96, p = 0.016). Age, histological type, tumor size, surgery, and FIGO stage were all independent prognostic factors for survival (p < 0.05 for all). Subgroup analysis demonstrated that RTCT was significantly associated with better survival in most subgroups, except for those with adenocarcinoma, tumor size ConclusionRTCT is significantly correlated with prolonged survival in patients with primary vaginal carcinoma. RTCT should be applied to most patients with primary vaginal carcinoma instead of RT alone, except for those with adenocarcinoma, tumor size |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|